Short Interest In Ironwood Pharmaceuticals Moves 11% Lower

The most recent short interest data has been released by the NASDAQ for the 05/31/2013 settlement date, which shows a 1,876,796 share decrease in total short interest for Ironwood Pharmaceuticals Inc. ( IRWD), to 15,213,886, a decrease of 10.98% since 05/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for IRWD at the 05/31/2013 settlement increased to 2,056,575, as compared to 833,580 at the 05/15/2013 report. That brought "days to cover" down to 7.40, a 63.92% decrease from the 20.50 days to cover calculated at the previous short interest data release.

START SLIDESHOW:
The 10 Most Shorted Stocks of the Dow »

The below chart shows the historical "days to cover" for IRWD at previous short interest release dates:

Loading+chart++2013+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where IRWD had been shorted as a hedge.

The chart below shows the one year performance of IRWD shares, versus its 200 day moving average. Looking at this chart, IRWD's low point in its 52 week range is $10.01 per share, with $19.67 as the 52 week high point — that compares with a last trade of $12.06.

Ironwood Pharmaceuticals Inc. Chart

According to the ETF Finder at ETF Channel, IRWD makes up 1.29% of the SPDR S&P Biotech ETF (XBI) which is higher by about 0.7% on the day Thursday.

In afternoon trading Thursday, IRWD was down about 1.9% on the day.

null

If you liked this article you might like

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Synergy Pharmaceuticals Secures Approval for Linzess Competitor